	US 12,153,057 B2
	Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
Darius Wilson, Loerrach (DE); and Stefan Kirsch, Berlin (DE)
Assigned to B.R.A.H.M.S GMBH, Hennigsdorf (DE)
Appl. No. 16/956,330
Filed by B.R.A.H.M.S GMBH, Hennigsdorf (DE)
PCT Filed Dec. 20, 2018, PCT No. PCT/EP2018/086130 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/122088, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 17209069 (EP), filed on Dec. 20, 2017.
Prior Publication US 2020/0319212 A1, Oct. 8, 2020
Int. Cl. G01N 33/74 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01)

CPC G01N 33/74 (2013.01) [G01N 33/502 (2013.01); A61K 45/06 (2013.01); G01N 2333/585 (2013.01); G01N 2800/26 (2013.01); G01N 2800/52 (2013.01)]

15 Claims

1. A method of treating a patient wherein the patient has one or more comorbidities wherein the method comprises

administering a pharmaceutical composition comprising one or more antibiotic agents,

wherein the patient is administered said pharmaceutical composition after being identified by the method by a method comprising:

providing a sample from said patient, and

measuring a level of PCT or fragment(s) thereof in said sample,

wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required

wherein the one or more comorbidities are selected from the group consisting of metabolic disorder (obesity), diabetes, immunodeficiency, renal disease, hypertension thrombosis, malignancy and cancer, and

wherein the patient is not suffering from an acute ischemic or hemorrhagic stroke.